Mycoplasma Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Mycoplasma Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The mycoplasma testing market is estimated to register a healthy CAGR of 13% over the forecast period, 2022-2027.

In recent times, countries have faced a huge threat of COVID-19. As per the World Health Organization (WHO), coronavirus disease is an infectious disease, and most people infected with the COVID-19 virus will experience mild to moderate respiratory illness. The study "The Prevalence of Mycoplasma Pneumoniae Among Children in Beijing Before and During the COVID-19 Pandemic" published in April 2022, stated that the M. pneumoniae outbreak started in the summer of 2019 in Beijing. After the COVID-19 pandemic outbreak at the end of 2019, the M. pneumoniae positive rates dropped dramatically. This was due to the restrictive measures of the COVID-19 pandemic, which effectively controlled the transmission of M. pneumonia. However, after the easing of COVID-19 restrictions, M. pneumonia is expected to increase further during the study period, thereby impacting the market growth.

Factors such as high spending in R&D activities by biopharmaceutical companies, increased government initiatives and funding in research activities, technological advancements, increasing demand for fast, accurate, and affordable testing, and the increasing cell culture contamination, are further driving the market for mycoplasma testing.

The study "Point-of-care molecular diagnosis of Mycoplasma pneumonia including macrolide sensitivity using quenching probe polymerase chain reaction" published in October 2021, stated that the Smart Gene system is a rapid and accurate assay for detection of the existence of M. pneumoniae and a point mutation at domain V of the 23S rRNA gene of M. pneumoniae at the same time. The Smart Gene system is suitable for point-of-care testing in both hospital and outpatient settings. Thus, such studies indicating the potential of diagnostic testing for mycoplasma pneumonia will increase their acceptance, thus driving the market.

In April 2022, AlphaBiolabs launched STI testing for members of the public and healthcare partners. The Complete Panel (7 STIs) detects chlamydia, gonorrhea, mycoplasma genitalium, mycoplasma hominis, trichomoniasis, and ureaplasma parvum (UTI), and urea urealyticum (UTI) bacterias. Therefore, the launch of such tests detecting mycoplasma bacteria will boost the market. Thus, due to the above-mentioned factors, the studied market is expected to grow significantly during the study period. However, there are certain stringent government regulations across several developed and emerging countries and a high degree of consolidation for new entrants, which are among the major hindrances in the growth of the mycoplasma testing market.

Key Market TrendsPolymerase Chain Reaction (PCR) is Expected to Hold a Significant Market Share Over the Forecast Period

North America currently dominates the mycoplasma testing market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future due to its well-established healthcare industry and the rising prevalence of respiratory diseases in the area. Other factors driving the growth of this region are the presence of global biotech companies and pharmaceutical players and higher investment in R&D activities in the region. The United States holds the majority of the market share in North America. This is due to the rising healthcare expenditure, along with the rapid adoption of point-of-care testing.

The launch of products in the country will also increase the mycoplasma testing procedures contributing to the market growth. For instance, in July 2020, bioMérieux launched BIOFIRE MYCOPLASMA, an innovative test for mycoplasma detection in the United States for pharmaceutical products used for biotherapeutics (antibodies, hormones, cell and gene therapies, etc.), the most vibrant sector in the pharmaceutical industry. Furthermore, in April 2020, Infinity Laboratories expanded its capabilities by launching Mycoplasma testing. Such adoption of critical strategies like expansion, partnerships, acquisitions, and others will expand the capabilities of the key market players, thereby driving the market growth.

Moreover, rising research and development studies proving the efficacies of diagnostic techniques in the United States are expected to drive market growth during the study period. For instance, in January 2021, Fujifilm and the Center for Advanced Biological Innovation and Manufacturing are investing about USD 76 million in Massachusetts for advanced research and development in cell and gene therapy, gene editing, immunotherapy, and biotechnology. Thus, owing to the above-mentioned factors, the studied market is expected to grow significantly in the region during the study period.

North America is Expected to Occupy a Significant Market Share Over the Forecast Period

North America currently dominates the mycoplasma testing market, and it is expected to continue its stronghold for a few more years. This region is expected to increase its market share due to its well-established healthcare industry and the rising prevalence of respiratory diseases. Other factors driving the growth of this region are the presence of global biotech companies and pharmaceutical players and higher investment in R&D activities in the region. The United States holds the majority of the market share in North America. This is due to the rising healthcare expenditure, along with the rapid adoption of point-of-care testing.

Launching products in the country will also increase the mycoplasma testing procedures contributing to the market growth. For instance, in July 2020, bioMérieux launched BIOFIRE MYCOPLASMA, an innovative test for mycoplasma detection in the United States for pharmaceutical products used for biotherapeutics (antibodies, hormones, cell and gene therapies, etc.), the most vibrant sector in the pharmaceutical industry.

Furthermore, in April 2020, Infinity Laboratories expanded its capabilities by launching Mycoplasma testing. Such adoption of key strategies like expansion, partnerships, acquisitions, and others will expand the capabilities of the key market players, thereby driving market growth.

Moreover, rising research and development studies proving the efficacies of diagnostic techniques in the United States are expected to drive market growth during the study period. For instance, according to the study "Evaluation of Commercial Molecular Diagnostic Methods for Detection and Determination of Macrolide Resistance in Mycoplasma pneumonia" published in May 2020, the highest clinical sensitivities were found with the InGenius PCR (99.5%) and the FilmArray RP (98.1%). Therefore, the presence of effective diagnostic techniques in the country is expected to boost mycoplasma testing and, in turn, is expected to drive the market. Thus, owing to the factors mentioned above, the studied market is expected to grow significantly in the region during the study period.

Competitive Landscape

The studied market is moderately competitive. Companies are focusing on various growth strategies, such as new product launches, collaborations, acquisitions, and partnerships, to enhance their market presence. The major players include Abbott, Agilent Technologies, Charles River Laboratories International Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd, Lonza Group, Merck KGaA, PromoCell GmbH, Sartorius AG, and Thermo Fisher Scientific Inc., among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.